SBS Stratec SE

31.37USD28.60 EUR · XETRA+4.57%Mkt Cap: 381.31M USDP/E: —

Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures auto…

Key Statistics

Company
Market Cap381.31M USD
Enterprise Value478.82M USD
Revenue (TTM)263.43M USD
Gross Profit70.44M USD
Net Income (TTM)-265.43K USD
Revenue/Share21.67 USD
Last Price31.37 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.4K
CountryDE
SectorHealthcare
IndustryMedical Devices
ISINDE000STRA555
Valuation
P/E (Trailing)—
P/E (Forward)15.73
PEG0.98
EV/EBITDA60.48
EV/Revenue1.82
P/S1.45
P/B1.78
EPS (TTM)-3.83 USD
EPS (Forward)1.99 USD
52W Range
17.8891% of range32.74
52W High32.74 USD
52W Low17.88 USD
Profitability
Gross Margin25.60%
Oper. Margin-10.68%
EBITDA Margin3.01%
Profit Margin-0.10%
ROE-0.10%
ROA-0.06%
ROIC1.55%
ROCE2.87%
Growth
Revenue Growth-8.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-474.91K USD
CapEx (TTM)17.80M USD
FCF Margin17.80%
FCF Yield12.30%
Net Debt97.51M USD
Net Debt/EBITDA12.32
Net Debt/FCF2.08
Balance Sheet
Debt/Equity0.56
Current Ratio3.76
Quick Ratio1.61
Book Value/Sh17.60 USD
Cash/Share1.91 USD
Dividends
Fwd Div Rate0.66 USD
Trail. Div Rate0.66 USD
Div. Yield2.22%
5Y Avg Yield1.56%
Payout Ratio47.24%
Ex-Div DateJun 24, 2026
Pay Date—
Splits
Last Split2.994:1
Split DateJul 31, 2006
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.41 USD
Upside (mean)+16.1%
Target Range28.52 USD – 42.78 USD
28.52+16.1% to mean42.78
# Analysts5
Ownership
Shares Out.12.16M
Float11.54M
Insiders63.06%
Institutions31.88%
Technical
SMA 5026.19 (+19.8%)
SMA 20022.31 (+40.6%)
Beta0.84
S&P 52W Chg12.00%
Avg Vol (30d)20.06K
Avg Vol (10d)22.92K
Technical Indicators
RSI (14)73.1
MACD1.2162
MACD Signal0.8968
MACD Hist.+0.3194
BB Upper31.74 USD
BB Middle27.62 USD
BB Lower23.49 USD
BB Width29.88%
ATR (14)1.256 USD
Vol Ratio (20d)2.34x

About Stratec (ETR: SBS)

›

Stratec (ETR: SBS) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,352 employees.

The shares were at 28.60 EUR on 19 November 2026, up 31.8% over 52 weeks. Its 52-week range is 16.30 EUR to 29.85 EUR: the price is 4.2% below the high and 75.5% above the low.

Its market capitalisation is 347.66M EUR. It pays a dividend yielding 2.22% (it pays out 47% of its earnings), against a median of 2.36% among the dividend payers in that peer group.

Stratec reports return on equity of -0.1%, an operating margin of -10.7% and revenue down 8.1% year over year.

Its debt exceeds its cash by 88.90M EUR, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 33.20 EUR is 16.1% above the current price. The next earnings report is expected on 27 April 2027.